- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02524379
Spinal Cord Injury Neuroprotection With Glyburide (SCING)
June 7, 2022 updated by: Ohio State University
Spinal Cord Injury Neuroprotection With Glyburide; Pilot Study: An Open-Label Prospective Evaluation of the Feasibility, Safety, Pharmacokinetics, and Preliminary Efficacy of Oral Glyburide (DiaBeta) in Patients With Acute Traumatic Spinal Cord Injury
The purpose of this study is to determine the safety of using oral Glyburide in patients with acute traumatic cervical spinal cord injuries (SCI).
Study Overview
Detailed Description
This study will include patients between 18 and 80 years who have experienced acute traumatic cervical spinal cord injury (specifically ASIA A, B or C).
Patients will then begin an oral drug regimen of Glyburide, which must be started within 8 hours of injury and continued for 72 hours at a daily dose of 3.125 mg on Day 1, 2.5 mg on Day 2 and 2.5 mg on Day 3. If indicated, the patient will also have surgical intervention for spinal cord decompression and spinal stabilization.
Each patient who takes part in this study will have labs drawn regularly and adverse events assessed daily through Day 14 or discharge (whichever is earlier).
Study participation will last for 365 days (+/- 30 days), with post-hospitalization follow-up occurring on Days 28, 42, 84, 182 and 365.
Study Type
Interventional
Enrollment (Actual)
3
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ohio
-
Columbus, Ohio, United States, 43210
- The Ohio State University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age: ≥ 18 years and ≤ 80 years
- Written informed consent by patient or legal authorized representative
- No other life-threatening injury
- No evidence of sepsis
- Acute cervical SCI with ASIA Impairment Scale grade A, B or C on admission
- Non-penetrating SCI at neurologic level from C2 to C8
- Initiation of study drug within 8 hours of injury
Exclusion Criteria
- Unconsciousness or other mental impairment that prevents neurological assessment within the first 8 hours
- Acute SCI with ASIA Impairment Scale grade D or E
- Currently involved in another non-observational SCI research study or receiving another investigational drug
- History of hypersensitivity to sulfonylureas, in particular glyburide, or any of its components
- Other illness (including mental disorder) that could preclude accurate medical and neurological evaluation (at discretion of the site investigator)
- Unable to commit to the follow-up schedule
- A recent history of regular substance abuse (illicit drugs, alcohol), which in the opinion of the investigator would interfere with the subject's participation in the study
- Any condition likely to result in the patient's death within the next 12 months
- Prisoner
- Severe renal disorder from the patient's history (e.g. dialysis) or baseline eGFR of < 30 mL/min/1.73 m2
- Known severe liver disease, or ALT > 3 times upper limit of normal or bilirubin > 2 times upper limit normal. Subjects may be randomized if liver function tests have been drawn but are not yet available and the subject has no known history of liver disease; however, treatment with DiaBeta will be discontinued prior to the second dose if liver function tests indicate ALT > 3 times upper limit of normal or bilirubin > 2 times upper limit of normal
- Blood glucose <55 mg/dL at enrollment or immediately prior to administration of DiaBeta, or a clinically significant history of hypoglycemia
- Acute ST elevation myocardial infarction, and/or acute decompensated heart failure, and/or QTc > 520 ms, and/or known history of cardiac arrest (PEA, VT, VF, asystole), and/or admission for an acute coronary syndrome, myocardial infarction, or coronary intervention (percutaneous coronary intervention or coronary artery surgery) within the past 3 months
- Known treatment with Bosentan within past 7 days
- Known G6PD enzyme deficiency
- Pregnancy: Women must be either post-menopausal, permanently sterilized or, if ≤ 50 years old, must have a negative test for pregnancy obtained before enrollment
- Breast-feeding women who do not agree to stop breast-feeding during and for 7 days following the end of oral glyburide administration
- Subjects who in the opinion of the investigator are not suitable for inclusion in the study (reason to be documented).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Glyburide Treatment Arm
Enrolled patients will receive 12 doses of Glyburide starting within 8 hours of SCI.
The dosing regimen involves an initial dose of 1.25 mg followed by eleven consecutive doses of 0.625 mg every 6 hours.
The total daily dose of Glyburide on Day 1, Day 2 and Day 3 will be 3.125 mg, 2.5 mg, and 2.5 mg respectively.
|
3 day drug regimen beginning 8 hours after acute traumatic spinal cord injury.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With tSCI Recruited Within the Specified Time Window
Time Frame: Enrollment Period (within 8 hours of tSCI)
|
A measure of feasibility of undertaking a larger phase II study among this population of patients where treatment must begin within a short injury-to-drug time window.
|
Enrollment Period (within 8 hours of tSCI)
|
Number of Drug Related Adverse Events
Time Frame: One year post enrollment
|
A measure of safety of treating patients with traumatic spinal cord injury with Glyburide administered orally within a short injury-to-drug time window.
|
One year post enrollment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Neurologic Recovery Following tSCI
Time Frame: One year post enrollment
|
The neurologic status of patients will be assessed using the American Spinal Injury Association (ASIA) Impairment Scale (AIS) as assessed by International Standards for Neurological Classification of SCI (ISNCSCI) criteria.
|
One year post enrollment
|
Serum Pharmacokinetic and Biomarker Analysis
Time Frame: Enrollment through post-treatment day 7
|
Plasma concentrations will be serially quantified through day 3 following tSCI to evaluate the pharmacokinetics of Glyburide in the acute tSCI population.
Comparisons will be made to reported levels achieved in healthy patient cohorts.
Standard enzyme-linked immunosorbent assay (ELISA) techniques will be used to measure blood levels of neurofilament light chain, neuron- specific enolase, tau, S100b, and glial fibrillary acidic protein levels on admission, at 24 hours and on days 3 and 7 following tSCI to evaluate serum biomarker levels.
Comparisons will be made to previously published values observed in non-treated control patients
|
Enrollment through post-treatment day 7
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: H. Francis Farhadi, MD, PhD, Ohio State University
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 14, 2017
Primary Completion (Actual)
February 8, 2021
Study Completion (Actual)
February 8, 2021
Study Registration Dates
First Submitted
August 13, 2015
First Submitted That Met QC Criteria
August 13, 2015
First Posted (Estimate)
August 14, 2015
Study Record Updates
Last Update Posted (Actual)
July 5, 2022
Last Update Submitted That Met QC Criteria
June 7, 2022
Last Verified
June 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2014H0335
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Undecided
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Spinal Cord Injury
-
University of British ColumbiaRecruitingSpinal Cord Injuries | Acute Spinal Cord Injury | Acute Spinal Paralysis | Trauma, Spinal CordCanada
-
Jill M. Wecht, Ed.D.Icahn School of Medicine at Mount SinaiRecruitingBlood Pressure | Spinal Cord Injuries | SCI - Spinal Cord Injury | Blood Pressure Disorders | Traumatic Spinal Cord Injury | Acute Spinal Cord Injury | Neuromodulation | Spinal Cord StimulationUnited States
-
Kringle Pharma, Inc.Recruiting
-
AlaMab Therapeutics (Shanghai) Inc.RecruitingAcute Spinal Cord InjuryChina
-
University of KentuckyRecruiting
-
University of British ColumbiaUnited States Department of DefenseRecruitingSpinal Cord Injuries | Acute Spinal Cord InjuryCanada
-
Pharmazz, Inc.Recruiting
-
Chinese Academy of SciencesThe First Affiliated Hospital of Soochow University; General Hospital of Ningxia... and other collaboratorsUnknownAcute Spinal Cord InjuryChina
-
University of CalgaryHotchkiss Brain Institute, University of Calgary; AANS/CNS Section on Disorders...TerminatedAcute Spinal Cord InjuryUnited States, Canada
-
Acorda TherapeuticsUnited States Department of Defense; DP Clinical, Inc.TerminatedAcute Spinal Cord Injury
Clinical Trials on Glyburide
-
Bristol-Myers SquibbCompletedDiabetes Mellitus, Non-Insulin-DependentUnited States
-
University of British ColumbiaNovo Nordisk A/SCompleted
-
Bristol-Myers SquibbCompletedDiabetes Mellitus, Non-Insulin-DependentUnited States
-
University of KentuckyRecruiting
-
University of Maryland, BaltimoreNot yet recruitingSarcoidosis, Pulmonary
-
GlaxoSmithKlineCompletedDiabetes Mellitus, Type 2United States, Germany, Canada, Belgium, Denmark, Spain, Ireland, Netherlands, United Kingdom, Hungary, Italy, France, Austria, Czechia, Norway, Finland, Sweden
-
University of WashingtonGlaxoSmithKline; Seattle Institute for Biomedical and Clinical ResearchCompleted
-
St. Paul Heart ClinicGlaxoSmithKlineCompletedType 2 Diabetes MellitusUnited States
-
Eunice Kennedy Shriver National Institute of Child...University of Pittsburgh; University of Washington; University of Texas; RTI International and other collaboratorsUnknownGestational Diabetes MellitusUnited States
-
Novo Nordisk A/SCompleted